$CSTL
CASTLE BIOSCIENCES INC

2020 Q1 Form 10-Q Financial Statement

#000144736220000053 Filed on May 11, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1
Revenue $17.42M $8.717M
YoY Change 99.82% 138.23%
Cost Of Revenue $2.391M $1.598M
YoY Change 49.62% 27.84%
Gross Profit $15.03M $7.119M
YoY Change 111.08% 195.89%
Gross Profit Margin 86.27% 81.67%
Selling, General & Admin $11.08M $6.047M
YoY Change 83.2% 43.98%
% of Gross Profit 73.72% 84.94%
Research & Development $2.913M $1.394M
YoY Change 108.97% 10.63%
% of Gross Profit 19.39% 19.58%
Depreciation & Amortization $91.00K $77.00K
YoY Change 18.18% -3.75%
% of Gross Profit 0.61% 1.08%
Operating Expenses $13.99M $7.441M
YoY Change 88.03% 35.54%
Operating Profit $1.036M -$322.0K
YoY Change -421.74% -89.56%
Interest Expense $764.0K $1.024M
YoY Change -25.39% -296.92%
% of Operating Profit 73.75%
Other Income/Expense, Net $0.00 -$33.00K
YoY Change -100.0% 65.0%
Pretax Income $570.0K -$1.360M
YoY Change -141.91% -62.53%
Income Tax $0.00 $0.00
% Of Pretax Income 0.0%
Net Earnings $570.0K -$1.358M
YoY Change -141.97% -62.59%
Net Earnings / Revenue 3.27% -15.58%
Basic Earnings Per Share $0.03 -$1.22
Diluted Earnings Per Share $0.03 -$1.22
COMMON SHARES
Basic Shares Outstanding 17.37M shares 1.917M shares
Diluted Shares Outstanding 18.73M shares 1.917M shares

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $98.70M $16.20M
YoY Change 509.26%
Cash & Equivalents $98.65M $16.23M
Short-Term Investments
Other Short-Term Assets $2.100M $700.0K
YoY Change 200.0%
Inventory $1.219M $800.0K
Prepaid Expenses
Receivables $14.60M $9.200M
Other Receivables $0.00 $0.00
Total Short-Term Assets $116.6M $27.00M
YoY Change 331.67%
LONG-TERM ASSETS
Property, Plant & Equipment $2.733M $1.700M
YoY Change 60.76%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $216.0K $700.0K
YoY Change -69.14%
Total Long-Term Assets $3.705M $4.000M
YoY Change -7.38%
TOTAL ASSETS
Total Short-Term Assets $116.6M $27.00M
Total Long-Term Assets $3.705M $4.000M
Total Assets $120.3M $31.00M
YoY Change 287.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.934M $1.600M
YoY Change 20.88%
Accrued Expenses $4.900M $3.800M
YoY Change 28.95%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $3.600M
YoY Change -100.0%
Long-Term Debt Due $8.333M
YoY Change
Total Short-Term Liabilities $15.26M $9.000M
YoY Change 69.51%
LONG-TERM LIABILITIES
Long-Term Debt $17.01M $23.60M
YoY Change -27.91%
Other Long-Term Liabilities $100.0K $1.200M
YoY Change -91.67%
Total Long-Term Liabilities $17.01M $24.80M
YoY Change -31.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.26M $9.000M
Total Long-Term Liabilities $17.01M $24.80M
Total Liabilities $32.32M $33.80M
YoY Change -4.37%
SHAREHOLDERS EQUITY
Retained Earnings -$51.64M
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $87.93M -$49.43M
YoY Change
Total Liabilities & Shareholders Equity $120.3M $31.00M
YoY Change 287.93%

Cashflow Statement

Concept 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income $570.0K -$1.358M
YoY Change -141.97% -62.59%
Depreciation, Depletion And Amortization $91.00K $77.00K
YoY Change 18.18% -3.75%
Cash From Operating Activities -$251.0K $1.288M
YoY Change -119.49% -151.31%
INVESTING ACTIVITIES
Capital Expenditures $500.0K $244.0K
YoY Change 104.92% -913.33%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$500.0K -$244.0K
YoY Change 104.92% 713.33%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $559.0K $10.71M
YoY Change -94.78% 100.13%
NET CHANGE
Cash From Operating Activities -$251.0K $1.288M
Cash From Investing Activities -$500.0K -$244.0K
Cash From Financing Activities $559.0K $10.71M
Net Change In Cash -$192.0K $11.75M
YoY Change -101.63% 318.19%
FREE CASH FLOW
Cash From Operating Activities -$251.0K $1.288M
Capital Expenditures $500.0K $244.0K
Free Cash Flow -$751.0K $1.044M
YoY Change -171.93% -142.1%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 cstl Contract With Customer Customer Payment Terms
ContractWithCustomerCustomerPaymentTerms
P30D
CY2019Q1 cstl Increase Decreasein Deferred Lease Liability
IncreaseDecreaseinDeferredLeaseLiability
14000 USD
CY2020Q1 cstl Increase Decreasein Deferred Lease Liability
IncreaseDecreaseinDeferredLeaseLiability
-2000 USD
CY2019Q1 cstl Incremental Common Shares Attributableto Dilutive Effectof Shares Issued Under Employee Stock Purchase Plan
IncrementalCommonSharesAttributabletoDilutiveEffectofSharesIssuedUnderEmployeeStockPurchasePlan
0 shares
CY2020Q1 cstl Incremental Common Shares Attributableto Dilutive Effectof Shares Issued Under Employee Stock Purchase Plan
IncrementalCommonSharesAttributabletoDilutiveEffectofSharesIssuedUnderEmployeeStockPurchasePlan
25000 shares
CY2019Q1 cstl Offering Costs And Debt Issuance Costs Incurred But Not Yet Paid
OfferingCostsAndDebtIssuanceCostsIncurredButNotYetPaid
463000 USD
CY2020Q1 cstl Offering Costs And Debt Issuance Costs Incurred But Not Yet Paid
OfferingCostsAndDebtIssuanceCostsIncurredButNotYetPaid
0 USD
CY2020Q1 cstl Revenue From Contract With Customer Revenue Not Yet Recognized Number Of Claims In Adjudication Process
RevenueFromContractWithCustomerRevenueNotYetRecognizedNumberOfClaimsInAdjudicationProcess
2698 claim
CY2020Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-03-31
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001447362
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17220032 shares
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
CASTLE BIOSCIENCES INC
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1865000 USD
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1934000 USD
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
14648000 USD
CY2020Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
14600000 USD
CY2019Q4 us-gaap Accounts Receivable Net Noncurrent
AccountsReceivableNetNoncurrent
870000 USD
CY2020Q1 us-gaap Accounts Receivable Net Noncurrent
AccountsReceivableNetNoncurrent
756000 USD
CY2019Q4 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
4785000 USD
CY2020Q1 us-gaap Accrued Bonuses Current And Noncurrent
AccruedBonusesCurrentAndNoncurrent
1794000 USD
CY2019Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
218000 USD
CY2020Q1 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
103000 USD
CY2019Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
79000 USD
CY2020Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
79000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1162000 USD
CY2020Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1123000 USD
CY2019Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
169000 USD
CY2020Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
92000 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1203000 USD
CY2020Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1293000 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
137308000 USD
CY2020Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
139559000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
8378000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
168000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1577000 USD
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
168000 USD
CY2020Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1577000 USD
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 USD
CY2020Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0 USD
CY2019Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
334000 USD
CY2020Q1 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
224000 USD
CY2019Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3000 USD
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0 USD
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10601000 shares
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
969000 shares
CY2019Q4 us-gaap Assets
Assets
119746000 USD
CY2020Q1 us-gaap Assets
Assets
120257000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
116681000 USD
CY2020Q1 us-gaap Assets Current
AssetsCurrent
116552000 USD
CY2019Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
83000 USD
CY2020Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
270000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
98845000 USD
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
98653000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4479000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16230000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98845000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98653000 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11751000 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-192000 USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17130907 shares
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17203496 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17130907 shares
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17203496 shares
CY2019Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
17000 USD
CY2020Q1 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
17000 USD
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-1358000 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
570000 USD
CY2019Q1 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
648000 USD
CY2020Q1 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
3160000 USD
CY2019Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1598000 USD
CY2020Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2391000 USD
CY2019Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
55000 USD
CY2020Q1 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
54000 USD
CY2019Q1 us-gaap Depreciation
Depreciation
77000 USD
CY2020Q1 us-gaap Depreciation
Depreciation
91000 USD
CY2019Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.22
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2019Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.22
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.03
CY2019Q1 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
-46000 USD
CY2020Q1 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
0 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5779000 USD
CY2020Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3134000 USD
CY2019Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-13000 USD
CY2020Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0 USD
CY2019Q1 us-gaap Gross Profit
GrossProfit
7119000 USD
CY2020Q1 us-gaap Gross Profit
GrossProfit
15027000 USD
CY2019Q1 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-1358000 USD
CY2020Q1 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
570000 USD
CY2019Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-329000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
56000 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3841000 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-161000 USD
CY2019Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1809000 USD
CY2020Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-2645000 USD
CY2019Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-73000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
119746000 USD
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
120257000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
15289000 USD
CY2020Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-19000 USD
CY2019Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
321000 USD
CY2020Q1 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-96000 USD
CY2019Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
14000 USD
CY2020Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
77000 USD
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
66000 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
129000 USD
CY2019Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2020Q1 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
27000 shares
CY2019Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2020Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1310000 shares
CY2019Q1 us-gaap Interest Expense
InterestExpense
1024000 USD
CY2020Q1 us-gaap Interest Expense
InterestExpense
764000 USD
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
184000 USD
CY2020Q1 us-gaap Interest Payable Current
InterestPayableCurrent
184000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
1237000 USD
CY2020Q1 us-gaap Inventory Net
InventoryNet
1219000 USD
CY2019Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
21000 USD
CY2020Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
298000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
34633000 USD
CY2020Q1 us-gaap Liabilities
Liabilities
32323000 USD
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
15256000 USD
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
5833000 USD
CY2020Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
8333000 USD
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
19289000 USD
CY2020Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
17013000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10707000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
559000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-244000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-500000 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1288000 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-251000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1358000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
570000 USD
CY2019Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2342000 USD
CY2020Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
570000 USD
CY2020Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
7441000 USD
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
13991000 USD
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-322000 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
1036000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1812000 USD
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
168000 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1577000 USD
CY2020Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1855000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
135000 USD
CY2020Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
216000 USD
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-33000 USD
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2019Q4 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
0 USD
CY2020Q1 us-gaap Other Sundry Liabilities Current
OtherSundryLiabilitiesCurrent
274000 USD
CY2019Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
244000 USD
CY2020Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
500000 USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2020Q1 us-gaap Preferred Stock Value Outstanding
PreferredStockValueOutstanding
0 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1951000 USD
CY2020Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2080000 USD
CY2019Q1 us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
4756000 USD
CY2019Q1 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
11695000 USD
CY2020Q1 us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0 USD
CY2019Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1000 USD
CY2020Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
71000 USD
CY2019Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0 USD
CY2020Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
488000 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3263000 USD
CY2020Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4026000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2060000 USD
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2733000 USD
CY2019Q1 us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
989000 USD
CY2020Q1 us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
0 USD
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1394000 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2913000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-52212000 USD
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-51642000 USD
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
8717000 USD
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
17418000 USD
CY2019Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6047000 USD
CY2020Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11078000 USD
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
856545 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
863127 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
1562672 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
716040 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.38
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
12200 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
26.59
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
169200 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
42704000 USD
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2637966 shares
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2762364 shares
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.30
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.46
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.16
CY2020Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
31.05
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
19643000 USD
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y3M27D
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
111571 shares
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
2.39
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y5M27D
CY2020Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
32602 shares
CY2020Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
603000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
71000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-56566000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-49433000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
85113000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
87934000 USD
CY2019Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
56000 USD
CY2020Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
0 USD
CY2019Q1 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
928000 USD
CY2020Q1 us-gaap Temporary Equity Dividends Adjustment
TemporaryEquityDividendsAdjustment
0 USD
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1917000 shares
CY2019Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1917000 shares
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18734000 shares
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18734000 shares
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1917000 shares
CY2019Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1917000 shares
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17372000 shares
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
17372000 shares
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#231f20;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates include revenue recognition, the valuation of stock-based compensation, assessing future tax exposure and the realization of deferred tax assets, the useful lives and recoverability of property and equipment, and contingent liabilities. The Company bases these estimates on historical and anticipated results, trends, and various other assumptions that the Company believes are reasonable under the circumstances, including assumptions as to future events. These estimates form the basis for making judgments about the carrying values of assets and liabilities and recorded revenues and expenses that are not readily apparent from other sources. Actual results could differ from those estimates and assumptions. The Company has considered the potential impact of the COVID-19 pandemic on its estimates and assumptions and while there was not a material impact to the Company&#8217;s condensed financial statements as of and for the three months ended March 31, 2020; the extent to which the COVID-19 pandemic may impact the Company&#8217;s estimates is uncertain and subject to change.</font></div></div>

Files In Submission

Name View Source Status
0001447362-20-000053-index-headers.html Edgar Link pending
0001447362-20-000053-index.html Edgar Link pending
0001447362-20-000053.txt Edgar Link pending
0001447362-20-000053-xbrl.zip Edgar Link pending
cstl-20200331.xml Edgar Link completed
cstl-20200331.xsd Edgar Link pending
cstl-20200331_cal.xml Edgar Link unprocessable
cstl-20200331_def.xml Edgar Link unprocessable
cstl-20200331_lab.xml Edgar Link unprocessable
cstl-20200331_pre.xml Edgar Link unprocessable
exhibit101-q12020.htm Edgar Link pending
exhibit102-q12020.htm Edgar Link pending
exhibit103-q12020.htm Edgar Link pending
exhibit311-q12020.htm Edgar Link pending
exhibit312-q12020.htm Edgar Link pending
exhibit321-q12020.htm Edgar Link pending
exhibit322-q12020.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
q12020.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending